Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pharmacogenetics and anticoagulant therapy.

Brian F Gage1, Charles S Eby

  • 1Division of General Medical Sciences, Washington University School of Medicine, St. Louis, MO 63110, USA. bgage@im.wustl.edu

Journal of Thrombosis and Thrombolysis
|February 5, 2004
PubMed
Summary

Genetic variations in cytochrome P450 2C9 impact warfarin dosing. Patients with specific single-nucleotide polymorphisms (SNPs) require lower initial warfarin doses or closer monitoring to prevent bleeding risks.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Time-to-start of anticoagulant therapy and mortality in pulmonary embolism.

Journal of thrombosis and haemostasis : JTH·2026
Same author

Risk factors for anticoagulant-related bleeding in cancer: traditional and cancer-specific factors.

Blood vessels, thrombosis & hemostasis·2025
Same author

Association of anticoagulant therapy with bleeding in patients with chronic liver disease: A case-cross over study using the National Veterans Health Administration database.

Thrombosis research·2025
Same author

A Combined Intravenous and Oral Metoprolol Regimen to Reduce Perioperative Myocardial Injury: The ORION Trial.

Anesthesia and analgesia·2025
Same author

Catheter and Surgical Ablation for Atrial Fibrillation : A Systematic Review and Meta-analysis.

Annals of internal medicine·2025
Same author

Identification and characterization of factor XI autoantibodies in 2 patients with systemic lupus erythematosus: insights into mechanisms of acquired factor XI deficiency.

Research and practice in thrombosis and haemostasis·2025

Area of Science:

  • Pharmacogenomics
  • Drug Metabolism

Background:

  • Warfarin and coumarin anticoagulants are primarily metabolized by the cytochrome P450 2C9 (CYP2C9) enzyme complex.
  • Common single-nucleotide polymorphisms (SNPs) in the CYP2C9 gene are known to influence drug metabolism and patient response.

Purpose of the Study:

  • To investigate the clinical implications of CYP2C9 genetic variations on warfarin therapy initiation.
  • To highlight the need for personalized dosing strategies to mitigate bleeding risks associated with warfarin.

Main Methods:

  • The study focuses on the association between common CYP2C9 SNPs and International Normalized Ratio (INR) levels during warfarin initiation.
  • Analysis considers clinical variables such as age, body surface area, and concomitant medications in warfarin dosing.

Main Results:

  • Patients carrying specific CYP2C9 SNPs exhibit an exaggerated elevation in INR during warfarin initiation.
  • This genetic predisposition increases the risk of bleeding events in patients undergoing warfarin therapy.

Conclusions:

  • Patients with known CYP2C9 SNPs should commence warfarin therapy at lower doses or undergo more frequent INR monitoring.
  • Developing a comprehensive dosing algorithm incorporating genetic and clinical factors is crucial for safe and effective warfarin induction, preventing hemorrhage.

Related Experiment Videos